About Syndax

We are a late-stage biopharmaceutical company leveraging recent scientific insights on our lead therapeutic candidate entinostat in the emerging field of immuno-oncology. Due to its distinctive mechanism and preclinical and clinical activity observed to date, we believe entinostat holds great promise as a cornerstone combination therapy for a broad range of cancers.